European Commission Approves Novo's Catalent Acquisition

The European Commission today cleared Novo Holdings A/S’s acquisition of Catalent, Inc. (Catalent), a New Jersey-headquartered global contract development and manufacturing organisation, and Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

Details of the acquisition were announced on February 5, 2024, whereby the company agreed to purchase three manufacturing sites. 

The Catalent stockholders approved the pending transaction on 29 May 2024. In addition, the acquisition has received approval from authorities in several jurisdictions.

The acquisition still awaits the satisfaction of other customary closing conditions, including obtaining more regulations for the transaction. Despite that, Novo Nordisk says it anticipates the transaction to be finalised at the end of 2024.